163 related articles for article (PubMed ID: 25372020)
1. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.
Cummings CT; Linger RM; Cohen RA; Sather S; Kirkpatrick GD; Davies KD; DeRyckere D; Earp HS; Graham DK
Oncotarget; 2014 Nov; 5(21):10434-45. PubMed ID: 25372020
[TBL] [Abstract][Full Text] [Related]
2. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
8. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
9. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology.
Rogers AE; Le JP; Sather S; Pernu BM; Graham DK; Pierce AM; Keating AK
Oncogene; 2012 Sep; 31(38):4171-81. PubMed ID: 22179835
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
11. Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation.
Guttridge KL; Luft JC; Dawson TL; Kozlowska E; Mahajan NP; Varnum B; Earp HS
J Biol Chem; 2002 Jul; 277(27):24057-66. PubMed ID: 11929866
[TBL] [Abstract][Full Text] [Related]
12. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner.
Fraineau S; Monvoisin A; Clarhaut J; Talbot J; Simonneau C; Kanthou C; Kanse SM; Philippe M; Benzakour O
Blood; 2012 Dec; 120(25):5073-83. PubMed ID: 23065156
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma.
Li Y; Wang X; Bi S; Zhao K; Yu C
Biochem Biophys Res Commun; 2015 Feb; 457(3):461-6. PubMed ID: 25596315
[TBL] [Abstract][Full Text] [Related]
14. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
15. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP
Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425
[TBL] [Abstract][Full Text] [Related]
16. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J; Yang C; Kireev D; Simpson C; Norris-Drouin J; Hull-Ryde EA; Janzen WP; Johnson GL; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2013 Nov; 12(11):2367-77. PubMed ID: 23997116
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
19. Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.
Xie S; Li Y; Li X; Wang L; Yang N; Wang Y; Wei H
Oncotarget; 2015 Apr; 6(11):9206-19. PubMed ID: 25826078
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
